However, we note that other PPARγ agonists have been reported to reduce RARRES2 mRNA levels in epididymal and mesenteric adipose tissue when administered to mice (Vernochet et al., 2009), and plasma chemerin levels when administered to patients with type 2 diabetes (Esteghamati et al., 2014). Here, RARRES2 is linked to type 2 diabetes mellitus.